Genetic Insights into Cardiomyopathy: From Mechanisms to Medicine

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Genetics".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 721

Special Issue Editors


E-Mail Website
Guest Editor
Herbert Wertheim College of Engineering, Gainesville, FL, USA
Interests: computational biology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Movement Sciences and Health, Usha Kundu, MD College of Health, University of West Florida, 11000 University Parkway, Pensacola, FL 32514, USA
Interests: exercise-induced cardiac protection against myocardial infarction and metabolic distress-induced cardiomyopathy

Special Issue Information

Dear Colleagues,

Cardiomyopathies represent a heterogeneous group of myocardial disorders with diverse genetic contributions and clinical manifestations. Despite shared genetic mutations across hypertrophic, dilated, restrictive, arrhythmogenic, and non-compaction subtypes, these conditions exhibit distinct phenotypic presentations and disease trajectories. Notably, identical genetic defects can manifest at vastly different ages, with variable progression in pediatric and adult patients, highlighting the critical need to elucidate their underlying genetic and molecular mechanisms. Rapid advancements in next-generation sequencing, multi-omics technologies, and precision medicine now offer unprecedented opportunities to integrate genetic insights into clinical practice. This Special Issue of Biomolecules will showcase groundbreaking research that advances our understanding of cardiomyopathy genetics and explores how genomic innovations are revolutionizing diagnostics, prognostication, and therapeutic strategies.

We welcome original research and comprehensive reviews addressing, but not limited to, the following topics:

  • Novel Gene and Variant Discovery: Identifying rare and common genetic variants, including mitochondrial genome contributions, across cardiomyopathy subtypes;
  • Advanced Genetic Diagnostics: Innovations in genetic testing, including polygenic risk scores and clinical applications of whole-genome sequencing;
  • Disease Pathogenesis and Modifiers: Mechanistic insights into modifier genes, epigenetic regulation (e.g., DNA methylation, histone modifications), and drivers of phenotypic variability;
  • Innovative Therapies: Cutting-edge interventions such as gene therapy (viral vectors, CRISPR-Cas9, RNA-based approaches), novel pharmacotherapies, and non-pharmacological strategies (e.g., exercise regimens).

We encourage the submission of original research articles and comprehensive reviews that explore these rapidly advancing frontiers. Your contributions will be pivotal in paving the way for improved diagnostics, refined risk stratification, and the development of more effective and personalized treatments for individuals affected by cardiomyopathies.

Dr. Xiao Fan
Prof. Dr. Youngil Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiomyopathy
  • genetics
  • epigenetics
  • genomics
  • genotype–phenotype correlation
  • genetic penetrance
  • precision medicine
  • mitochondria
  • personalized treatment
  • gene therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1666 KB  
Article
Epigenetic Drugs Splitomicin, Suberohydroxamic Acid, CPTH6, BVT-948, and PBIT Moderate Fibro-Fatty Development in Arrhythmogenic Cardiomyopathy
by Melania Lippi, Silvia Moimas, Luca Braga, Yohan Santin, Arianna Galotta, Mauro Giacca, Giulio Pompilio and Elena Sommariva
Biomolecules 2025, 15(11), 1565; https://doi.org/10.3390/biom15111565 - 6 Nov 2025
Viewed by 554
Abstract
Arrhythmogenic cardiomyopathy (ACM) is a cardiac disorder manifesting through electrical and contractile dysfunction of the ventricles, characterized by fibro-fatty substitution of the myocardium. Cardiac mesenchymal stromal cells (CMSCs) are key contributors to this remodeling. In clinical management, several pharmacological approaches address ACM arrhythmias [...] Read more.
Arrhythmogenic cardiomyopathy (ACM) is a cardiac disorder manifesting through electrical and contractile dysfunction of the ventricles, characterized by fibro-fatty substitution of the myocardium. Cardiac mesenchymal stromal cells (CMSCs) are key contributors to this remodeling. In clinical management, several pharmacological approaches address ACM arrhythmias and heart failure, but, to date, none specifically target fibro-adipose replacement. Despite genetic origin, several studies have reported that non-genetic aspects influence ACM phenotype, including epigenetic factors. Little is known about their mechanisms in ACM and their potential therapeutic applications. In this work, we aimed to test whether, by perturbing the epigenetic landscape of ACM CMSCs, we could influence their propensity to fibro-fatty differentiation. We conducted a hypothesis-free screening of 157 epigenetic drugs on CMSCs, isolated from ACM patients. Through fluorescence assays, we evaluated lipid droplet accumulation, collagen deposition, and cell viability. Of the 157 drugs screened, five (splitomicin, suberohydroxamic acid, CPTH6, BVT-948, and PBIT) attenuated adipogenic differentiation of ACM CMSCs, with BVT-948 and CPTH6 also reducing collagen production. Overall, this study identified specific epigenetic drugs that were effective in reducing the fibro-fatty phenotype of ACM stromal cells, thus offering potential for adjunctive therapies in the clinical management of ACM patients. Full article
(This article belongs to the Special Issue Genetic Insights into Cardiomyopathy: From Mechanisms to Medicine)
Show Figures

Figure 1

Back to TopTop